Cannabis Rescheduling Delivers Narrow 280E Tax Relief, Not Industry-Wide Win

The Trump administration's decision to reschedule marijuana from Schedule I to Schedule III will provide tax relief for some cannabis businesses—but the majority of plant-touching operators will remain stuck with Section 280E restrictions.

The rescheduling represents the most significant federal cannabis policy shift in decades. Yet tax attorneys and industry analysts warn that only vertically integrated businesses with distinct corporate structures stand to benefit immediately from the change.

"The assumption that rescheduling automatically eliminates 280E for the entire industry is simply incorrect," said Andrew Kline, a cannabis tax attorney at Perkins Coie. "The reality is far more nuanced and depends entirely on how a business is structured."

Who Actually Benefits

Section 280E of the tax code prohibits businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses. Moving cannabis to Schedule III removes this barrier—but only for businesses directly engaged in activities now permitted under the new classification.

Vertically integrated operators that maintain separate entities for cultivation, manufacturing, and retail will see the most immediate relief. Their cultivation and production arms can now deduct standard business expenses like rent, utilities, and employee salaries. But their retail dispensaries? Those operations remain subject to 280E because they're still selling a federally controlled substance.

The distinction matters enormously. Cultivation and manufacturing businesses typically operate on tighter margins and higher overhead costs. Access to normal tax deductions could improve their bottom lines by 15-30%, according to cannabis accounting firms that have modeled the scenarios.

But dispensaries—which make up the bulk of licensed cannabis operators nationwide—see minimal benefit. They're still selling Schedule III controlled substances to consumers, which keeps them squarely within 280E territory.

The Math Behind the Limited Relief

Industry data shows approximately 14,000 licensed dispensaries operate across legal states, compared to roughly 3,500 cultivation facilities and 2,800 manufacturing operations. That means the rescheduling's tax benefits reach fewer than one-third of plant-touching businesses.

Even those numbers overstate the relief. Many cultivation and manufacturing businesses operate as subsidiaries of larger retail-focused companies. Complex corporate structures mean the tax savings might not translate to operational improvements.

"We're talking about incremental relief for a segment of the industry, not the transformative change many anticipated," said Leslie Bocskor, managing partner at Electrum Partners, a cannabis-focused advisory firm.

The Congressional Research Service estimated that full 280E repeal could save the cannabis industry $1.5-2 billion annually. Rescheduling to Schedule III? That figure drops to roughly $400-600 million, concentrated among cultivation and manufacturing operations.

What Comes Next

The rescheduling process still faces administrative hurdles. The Drug Enforcement Administration must complete its review and publish final rules, a process that could take 6-12 months even with administration support.

Meanwhile, cannabis industry advocates continue pushing for broader reform. The Secure and Fair Enforcement (SAFE) Banking Act and the Cannabis Administration and Opportunity Act both include provisions for complete 280E repeal.

"Rescheduling is a step forward, but it's not the finish line," said Aaron Smith, co-founder of the National Cannabis Industry Association. "We need comprehensive reform that treats cannabis businesses like any other legitimate industry."

Some tax experts suggest businesses should begin restructuring now to maximize potential benefits. That might mean separating cultivation operations into distinct legal entities or reorganizing manufacturing divisions. But those moves require capital and legal expertise many smaller operators lack.

The limited scope of 280E relief under rescheduling underscores a broader challenge: incremental federal cannabis reform creates winners and losers within the industry itself. Large, well-capitalized operators with sophisticated corporate structures capture the benefits. Smaller, single-license businesses continue shouldering the full tax burden.

For now, the industry waits on DEA rulemaking while calculating what rescheduling actually means for their specific operations. The answer, for most, falls short of the sweeping relief many had hoped for.

---

This article is based on original reporting by mjbizdaily.com.